Edgewise Therapeutics, Inc. (EWTX): Nasdaq/NYSE listing notice — Edgewise receives Nasdaq notice for audit committee non-compliance; cure period until June 2024

Edgewise Therapeutics, Inc.

Notice on July 10, 2023 from Nasdaq: audit committee fell below 3 members after Dr. Kenneth Harrison resigned from board and audit committee on June 19, 2023.
Cure period: until earlier of next annual shareholders' meeting or June 19, 2024; if annual meeting before Dec 18, 2023, then compliance needed by Dec 18, 2023.
Company intends to rely on cure period and is evaluating board and committee composition to regain compliance.
Failure to cure could result in delisting; company may appeal to a Hearings Panel.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Edgewise Therapeutics, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2), 5605(c)(4)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: audit committee
Rules: 5605(c)(2), 5605(c)(4)

Exact text from the filing

July 10, 2023, Edgewise Therapeutics, Inc. (the “Company”) received a notice (the “Notice”) from The Nasdaq Stock Market LLC (the “Nasdaq”) stating that, as a result of the resignation of Kenneth Harrison, Ph.D. (the “Director Resignation”) from the Board of Directors of the Company (the “Board”) and the Audit Committee of the Board (the “Audit Committee”), effective June 19, 2023 (as previously disclosed), the Company is no longer in compliance with the Nasdaq Listing Rule 5605, including the Nasdaq Listing Rule 5605(c)(2), which requires the Audit Committee to consist of at least three membe

View on SEC.gov

Browse all listing & compliance notices →

Edgewise Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-081202

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.